A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animalsRBD 영역에 결합할 수 있는 SARS-CoV-2 나노바디는 동물의 COVID-19 치료에 사용될 수 있습니다Article Published on 2022-07-012022-09-11 Journal: Research in veterinary science [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료법, [키워드] animals binding caused cells coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 disease in vitro in vivo infecting Infectious virus microorganism microorganisms nanobodies nanobody neutralizing antibody Prevent pseudovirus pseudoviruses RBD RBD protein respiratory S protein SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 Spike RBD protein SARS-CoV-2. Severe acute respiratory syndrome spike the RBD the SARS-CoV-2 therapeutic effects therapeutic potential Treatment treatment of COVID-19 was obtained was used [DOI] 10.1016/j.rvsc.2022.02.003 PMC 바로가기 [Article Type] Article
Non-glycosylated SARS-CoV-2 RBD elicited a robust neutralizing antibody response in mice글리코실화되지 않은 SARS-CoV-2 RBD는 마우스에서 강력한 중화 항체 반응을 유도했습니다Article Published on 2022-07-012022-09-12 Journal: Journal of Immunological Methods [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] adjuvant Analysis Antibody Response binding activity candidate vaccine CpG Delta domain Efficacy elicited enzyme Escherichia Escherichia coli glycosylated HPLC immune response Inclusion induce mice neutralized Neutralizing activity neutralizing antibody Neutralizing antibody response omicron overexpressed produced protective immunity protective neutralizing antibody Protein provided pseudovirus pseudoviruses purification RBD Receptor-binding domain Receptor-binding domain (RBD) robust SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2. the RBD Vaccine was obtained wild-type [DOI] 10.1016/j.jim.2022.113279 PMC 바로가기 [Article Type] Article
Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization인간 또는 동물 ACE2 매개 바이러스 진입 및 중화에 대한 우려의 SARS-CoV-2 변이체에서 스파이크 돌연변이의 영향Article Published on 2022-06-292022-09-11 Journal: Microbiology Spectrum [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 ACE2 receptor acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Affect angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 animal animals antibodies antibody Antibody neutralization antibody neutralization activity Beta caused cell entry cell line cell lines circulating common strain comparable concern coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic Delta determine Effect Effectiveness Efficiency Express expressing global health Health host range Human human ACE2 Impact infect infecting information mink MOST Mutation neutralization neutralizing antibody Neutralizing titer neutralizing titers nine omicron Omicron variant over pandemic parental Protein pseudovirus pseudoviruses public policy reduced respiratory reveal S protein S proteins SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 mutation SARS-CoV-2 S protein SARS-CoV-2 spike SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 virus sera several variant several variants severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 shown significantly socioeconomics spike spike mutations Spread Substitution substitutions Support susceptible tested the S protein the SARS-CoV-2 the SARS-CoV-2 virus therapeutic therapeutic antibodies Transmissibility Transmission Vaccine variant variants variants of concern variety Viral viral cell viral entry viral neutralization virulence virus virus entry virus replication Virus replication. VoC VOCs zoonotic [DOI] 10.1128/spectrum.01789-21 PMC 바로가기 [Article Type] Article
Host chitinase 3-like-1 is a universal therapeutic target for SARS-CoV-2 viral variants in COVID-19숙주 키티나제 3-유사-1은 COVID-19의 SARS-CoV-2 바이러스 변이체에 대한 보편적인 치료 표적입니다Article Published on 2022-06-232022-09-11 Journal: eLife [Category] COVID19(2023년), SARS, 변종, [키워드] accumulate ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Alpha anti-CHI3L1 antibody Antibody neutralization Beta breakthrough infections caused Cell CHI3L1 chitinase Concentration coronavirus disease Coronavirus disease 2019 Coronavirus-2 COVID-19 defined Delta delta variant demonstrated determine effective inhibitor epithelial epithelial cell Express FRG genetic variability host tissue induce Infection Infectious disease inhibit inhibitor Intervention kasugamycin Laboratory lethal disease Microbiology morbidity and mortality neutralization omicron priming protease pseudovirus pseudovirus pseudoviruses S protein SARS-CoV-2 viral Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe disease spike stimulate strain susceptibility the disease therapeutic target Therapeutics Transmissibility variant variants variants of concern viral variant viruses viruses. VoC Waves worldwide pandemic [DOI] 10.7554/eLife.78273 PMC 바로가기 [Article Type] Article
Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants오미크론 포함 SARS-CoV-2 변이체에 대한 의사 바이러스 기반 중화 분석 개발Article Published on 2022-06-182022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Alpha antibodies approved backbone Beta biosafety BSL-2 candidate collection time conditions conducted convalescent Convalescent patients convalescent plasma COVID-19 convalescent patient COVID-19 pandemic Developing drugs effective Efficiency expression plasmid full-length Gamma Genome Health HIV HIV-1 immune evasion in vitro luciferase reporter gene monoclonal antibodies neutralization Neutralization assay Neutralizing antibodies neutralizing capacity omicron parameter Particles Plasmid Prevention and control Protein pseudovirus Pseudovirus neutralization assay pseudovirus. pseudoviruses reduced REGN10933 REGN10987 reporter gene S protein expression plasmids S309 SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Spread the S protein therapeutic Vaccine Vaccines variant was tested Wuhan [DOI] 10.3390/v14061332 PMC 바로가기 [Article Type] Article
Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529신흥 SARS-CoV-2 변이체 B.1.1.529의 스파이크 당단백질의 기능적 특성Article Published on 2022-06-142022-09-11 Journal: Cell Reports [Category] COVID19(2023년), SARS, 변종, [키워드] ACE2 ACE2 affinity ACE2 binding acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 B.1.1.529 B.1.617.2 Cell coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 CP: Immunology CP: Microbiology cytopathic effects D614G decrease exhibit functional glycoprotein higher affinity immune evasion immunology Infection less Microbiology neutralization neutralization sensitivity omicron Patient prevalent processing property pseudovirus pseudoviruses relative S glycoprotein S glycoproteins S trimer S1 shedding SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sera severe acute respiratory syndrome Coronavirus spike glycoprotein stability syncytium formation temperature TMPRSS2 TMPRSS2 expression Transmission unliganded vaccinees variant variants variants. virion [DOI] 10.1016/j.celrep.2022.110924 PMC 바로가기 [Article Type] Article
Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infectionMVA 기반 백신의 비강내 접종은 IgA를 유도하고 SARS-CoV-2 감염으로부터 hACE2 마우스의 호흡기를 보호합니다Article Published on 2022-06-142022-09-11 Journal: Proceedings of the National Academy of Sciences of [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome administration Antigen Beta Blood CD3 CD8 coronavirus coronavirus 2 coronavirus vaccine COVID-19 COVID-19 pandemic current effective expressing firefly luciferase hACE2 IFN-γ IgA IgG immune responses Immunity immunized Immunoglobulin immunoglobulin A Immunoglobulin G induce Infection Infectious virus intramuscular intramuscular vaccination intramuscularly intranasal intranasally K18-hACE2 less luciferase Luminescence lung Lungs mice modified vaccinia virus morbidity mucosal mucosal immunity nasal turbinate nasal turbinates neutralized Neutralizing antibodies neutralizing antibody omicron Prevent prevented priming PROTECT protective immune response pseudovirus pseudoviruses raise remained respiratory respiratory immunity respiratory tract S protein S proteins SARS-CoV-2 SARS-COV-2 infection serum severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severity T cells the S protein Transmission upper respiratory tract vaccination Vaccine vaccinia virus vaccinia virus. variants Viral while Wuhan [DOI] 10.1073/pnas.2202069119 PMC 바로가기 [Article Type] Article
Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 우려 변종에 대한 CpG-보강 S-2P 소단위 백신의 중화 능력 평가Article Published on 2022-06-102022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), MERS, SARS, 변종, 비임상, 진단, [키워드] Ability acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Against Alpha Alpha variant aluminum aluminum hydroxide antibody Antigen Beta Beta variant beta variants breath clinical trial coated with concern coronavirus coronavirus 2 COVID-19 CpG D614G demonstrated dose effective Effectiveness elicit elicited Evaluating High dose Human humans hydroxide immune response immunization immunized immunogenicity medium neutralization neutralization ability neutralization activity Neutralizing antibodies neutralizing antibody neutralizing capacity Neutralizing titer neutralizing titers Phase 1 prefusion pseudovirus pseudoviruses RAT RATs reduced reduction reduction in respiratory retained S-2P SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variants serum antibodies serum antibody serum sample serum samples severe acute respiratory syndrome Coronavirus significantly Spike protein subject subunit subunit SARS-CoV-2 vaccine the SARS-CoV-2 Vaccine Vaccines variant Variant of concern. variants VOCs wild-type [DOI] 10.1093/cid/ciab711 PMC 바로가기 [Article Type] Article
The Cross-Protective Immunity Landscape Among Different SARS-CoV-2 Variant RBDs다양한 SARS-CoV-2 변종 RBD 간의 교차 보호 면역 환경Article Published on 2022-06-102022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Alpha antibody Antigen antigens Beta COVID-19 vaccine design cross-neutralization cross-neutralizing cross-protective cross-protective immunity Delta effective evaluated expressed IgG antibodies immune protection immunize Lambda landscape mice neutralization neutralization antibodies Neutralizing activity new SARS-CoV-2 omicron pentavalent pseudovirus pseudoviruses RBD RBD antigen RBD protein SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines SARS-CoV-2 variant SARS-CoV-2 variants the epidemic These data titers of IgG Vaccine vaccine strain Vaccines variant Variant. variants wild type [DOI] 10.3389/fimmu.2022.898520 PMC 바로가기 [Article Type] Article
Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2체외 세포 모델의 적절한 선택은 SARS-CoV-2에 대한 중화 항체 반응의 특성화에 영향을 미칩니다Article Published on 2022-06-072022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] antibody Antibody Response BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine Calu Calu-3 cell line cell lines cellular characterization characterized choice collected correlation COVID-19 COVID-19 vaccine Cytopathic effect cytopathic effects demonstrated Entry mechanism entry mechanisms evaluated in vitro increasingly inhibitory activity lack mechanisms Model mRNA mRNA vaccine natural infection Neutralizing Neutralizing activity neutralizing activity. occur of BNT162b2 PCR pseudovirus pseudoviruses response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants SARS-CoV-2 viral Selection sera Single Cell subject Surrogates TMPRSS2 vaccine-induced antibodies vaccine-induced antibody variants Vero Vero E6 Viral viral entry viral entry pathway virus particles VOCs [DOI] 10.3390/v14061232 PMC 바로가기 [Article Type] Article